JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - VAXCYTE INC
Financial Performance:
- No specific revenue, profit, or cash flow figures were disclosed, as the company is pre-revenue and focused on clinical development.
- The company aims to launch a BLA filing in H1 2028 for Vax31 (adult), with commercial revenue generation expected to begin in 2029.
- Management noted the global pneumococcal conjugate vaccine (PCV) market is currently valued at $8–$8.5 billion, expected to grow to $12 billion+ by 2029–2030, driven by adult market expansion.
Guidance and Future Outlook:
- Pivotal Phase 3 adult data for Vax31 (broadest spectrum PCV) is obtained; BLA filing targeted for H1 2028.
- Phase 2 infant data for Vax31 expected in H1 2026 to inform Phase 3 design.
- Four Phase 3 studies comprise the adult BLA: one pivotal (completed), two complementary (Opus 2 & 3), and one CMC consistency study (launch expected 2027).
- Preference for a "one fell swoop" BLA filing rather than rolling submission, though rolling submission remains an option.
- Long-term goal to capture market share in adult immunization, projected to grow from one-third to half of the global PCV market.
Business Segments and Product Lines:
- Vax31 (Lead Program): 31-valent pneumococcal conjugate vaccine; designed to expand coverage to >90% of circulating disease vs. ~60% for current 20/21-valent standards without degrading immune responses to overlapping serotypes.
- Adult Segment: Focus on expanding coverage beyond age 50; includes studies on co-administration with flu vaccine (Opus 2) and revaccination for previously immunized patients (Opus 3).
- Infant Segment: Comparing Vax31 against Prevnar 20; utilizing higher doses to improve immune responses; expecting net neutral or positive results similar to predecessor Vax24.
- Group A Strep: Another novel program with "blockbuster potential" currently in the clinic.
Market and Competitive Landscape:
- Market Dynamics: Adult immunization market is highly concentrated (retail pharmacies and large health systems represent >75% of volume).
- Competition: Competing with 20-valent (Prevnar 20) and 21-valent (Vaxneuvance) vaccines; competitor data on 25-valent vaccines shows higher serotype 3 responses but unclear clinical impact.
- Commercial Strategy: Targeting ~200 major US accounts; leveraging existing contracting templates that allow for innovation insertion post-approval.
- Historical Precedent: Market history suggests rapid adoption of higher-valency vaccines (e.g., Prevnar 20 gaining >90% market share despite Vaxneuvance having higher serotype 3 responses).
Risks and Challenges:
- Regulatory Uncertainty: ACIP (Advisory Committee on Immunization Practices) is not functioning normally; reliance on alternative bodies (AMA, Vaccine Integrity Project, AAFP) for recommendations.
- Clinical Hurdles: Need to maintain non-inferiority on overlapping serotypes while adding 11 new serotypes; potential trade-offs in immune response.
- Serotype 3: Identified as recalcitrant; higher antibody responses to serotype 3 in other vaccines have not historically translated to clinical or commercial benefit.
- Supply Chain: Manufacturing consistency study will use material from Lonza's multi-use facility; a second fully operational facility will be unlocked post-launch for commercial capacity.
Management Commentary and Tone:
- Tone described as "very strong" and highly confident regarding the paradigm shift of expanding coverage without trade-offs.
- CEO Grant Bickering expressed excitement over pivotal success and the "broadest spectrum" status of Vax31.
- CCO Mike Mullet highlighted the maturity of the commercial launch pathway and confidence in securing contracting with major health systems.
- Management emphasized the strategic advantage of launching a higher-valent vaccine in a market proven to prefer broader coverage.
Analyst Questions and Answers:
- BLA Strategy: Confirmed a full BLA filing in H1 2028; CMC consistency study to be launched in 2027 using Lonza materials.
- Revaccination: Discussed the potential for ACIP to recommend a second dose for adults as they age; data package to be submitted post-approval to support this case.
- Infant Data: Clarified expectations for H1 2026 infant data; high confidence in incremental serotype performance and dose-response improvements.
- Market Ramp: Compared launch velocity to Capvaxiv (45% market share in first 12 months); anticipate rapid market share acquisition for Vax31 in adults.
- Serotype 3: Dismissed the significance of higher serotype 3 responses in 25-valent competitors due to lack of proven clinical benefit and precedent of broader valency success (Prevnar 20).
- Data Release: Leaning toward concurrent unblinding of primary series and booster data for infants in 2026, with a final decision in early 2026.
Other Key Points:
- Vax31 is the first vaccine to successfully demonstrate broader spectrum coverage in adults without immune response degradation.
- The adult PCV market is the primary growth driver, shifting from infant-dominated (2/3) to a more balanced 50/50 split over the next 5–6 years.
- Contracting for vaccine distribution is facilitated by existing "innovation" clauses in health system agreements, allowing new products to enter quickly post-approval.
- Company
- VAXCYTE INC
- Keywords
- VAXCYTE INC